Copy to clipboard 
Orthopedic product development has never been a straight line, but today’s development teams are navigating a course that grows more complex with each product cycle. Advanced biomaterials, AI-driven design tools and enabling technologies are opening extraordinary opportunities while simultaneously multiplying the points where a product development program can go awry.
At the same time, escalating regulatory requirements are demanding more documentation and validation and increased strategic foresight than what’s accounted for in most development timelines.
The result is a product development environment where the old approach of addressing risks as they surface is no longer sustainable. Leading teams are shifting to an integrated model — one that maps technical, regulatory, clinical and supply chain risks in real time from the earliest stages of a program. The payoff is measured not only in launches that hit their targets, but also in the avoidance of costly surprises, redesigns and submission delays that can derail years of investment.
With proper planning from the start, R&D and development teams can build the risk infrastructure needed to protect the company’s timelines and bottom line.
Hiding in Plain Sight
When product teams consider development risk, they typically focus on material performance, regulatory submissions and supply chain reliability. Intellectual property (IP) rarely tops that list. That’s a mistake with severe consequences.
Andrea Davis, Managing Director of Bodkin IP, has spent her career helping orthopedic innovators understand the IP landscape before they get too far down the road to change course. In her experience, the companies that end up in the most difficult positions are the ones that treat IP strategy as an afterthought.
“The highest-impact risks don’t appear at one magical stage of development,” she said. “Rather, they creep in anywhere the company decides to defer doing their homework.”
Already at the concept stage, a team can lock itself into a crowded design space, building toward features that are claimed by someone else’s patents. The further the program progresses without addressing this risk, the more expensive the reckoning will be.
The most common version of this mistake, Davis said, is conflating patent ownership with market freedom, and the commercial stakes of this gap are significant. The solution is to build IP risk management into the development process from the very beginning and keep it there throughout the program. Freedom-to-Operate (FTO) searches often turn up potential IP barriers to product commercialization.
For teams working in increasingly crowded segments in which well-capitalized OEMs and surgeon-inventors are filing continuously, the competitive IP landscape shifts quickly. An FTO search conducted at ideation may look very different 18 months later when a design is maturing toward design freeze. Monitoring matters as much as initial assessment.
“A real commercial risk is launching a device or platform on a shaky IP foundation — no early, professional FTO search, no design-around work, no invalidity back-up plan and no ongoing watch as big ortho players and surgeon-entrepreneurs keep filing in the same niche,” Davis said.
According to Davis, early patent landscape and patentability work helps you understand who’s doing what in your niche, where your real points of novelty are and which directions are dead on arrival. She said layering in staged, professional FTO searches and patent filing strategies as the design matures lets you adjust your device early on and ensure a low-risk IP undertaking.
Early Considerations
For Dymphy van der Wilk, Ph.D., New Business Developer and Project Engineer at BAAT Medical, risk mapping is inseparable from development planning. BAAT’s model, structured around five sequential development phases, positions the first two stages — explore and design — as the highest-risk portion of any program.
After design freeze, Dr. van der Wilk noted, the path toward certification becomes considerably more predictable for teams with experience. It’s what happens before that freeze that determines whether a program is built on solid ground.
The logic is straightforward. Before the design freeze, almost everything is still in motion. The clinical requirements must be met. The economics must be penciled out. The supply chain must be selected and qualified. And the regulatory pathway must be understood well enough to build toward it. The more uncertainty that remains unresolved in these early phases, the more expensive it becomes to course correct later.
“In the beginning, you don’t have your design or manufacturers, so you need to select a supplier that fits with your design, but also with the market potential you want to reach at product launch,” Dr. van der Wilk said. This early-phase interdependency creates a particularly acute challenge around supply chain strategy. The market a company is targeting shapes which manufacturing infrastructure makes sense and, by extension, which suppliers to engage, and when.
A product targeting FDA 510(k) clearance may require a fundamentally different supply chain architecture than one pursuing CE marking under the EU MDR, and building on the wrong foundation can create compounding problems down the line.
For startups, Dr. van der Wilk noted, the challenge goes beyond development planning. Exit strategy, funding structure and regulatory approach are interconnected risk factors that must be considered from the outset.
“You need to think at the beginning about your exit strategy and the smart choices to make in your development, not only in terms of budget planning, but how you structure your whole organization,” she said.
The distinction between U.S. and EU regulatory pathways is particularly relevant here, according to Dr. van der Wilk. She said a 510(k) clearance is a transferable technical dossier that can move relatively cleanly if a startup is acquired. CE Marking under the EU MDR, by contrast, is tied to the qualifying organization’s quality management system, a transition that demands full recertification by a new owner and can significantly complicate an exit. Understanding that distinction is not a legal technicality; it’s a commercial risk that must be weighed at the concept stage.
One principle to which Dr. van der Wilk returns repeatedly is disciplined focus in the early development phases. Rather than front-loading QMS development, supplier qualification and technical documentation before a fundamental product concept is validated, teams are better served by first establishing a clear framework for what the product should solve, who will pay for it and at what target price point. That framework becomes the decision filter for everything that follows, and makes the downstream work faster.
Navigating the Regulatory Pathways
The best risk mitigation strategy, Dr. van der Wilk and other experts consistently emphasize, is early and deliberate engagement with regulatory bodies and working with partners with significant expertise in the area who know what the common pitfalls are and how to navigate around them.
FDA’s Q-Submission (Q-Sub) program offers a formal mechanism for this kind of early dialogue. By filing a pre-submission that outlines the planned approach to testing, verification and validation, development teams can receive substantive feedback before investing in the full testing program. The difference in outcome between teams that use this tool well and those that go in without guidance can be dramatic.
Dr. van der Wilk described a case in which a customer approached FDA directly — without the benefit of experienced guidance — to ask what clinical data would be needed for a PMA pathway. The agency responded with a requirement of 600 patients.
Working with an experienced development partner, a comparable device in a comparable situation might have achieved a successful regulatory outcome with a study population closer to 50. That gap translates into years of additional time and millions of U.S. dollars in clinical study costs.
For novel technologies, FDA’s Breakthrough Device Designation program offers another powerful risk management tool. In addition to the designation itself, which can accelerate product reviews, the program opens an ongoing communication channel with FDA reviewers who become genuinely invested in the program’s progress.
Validation infrastructure is another underutilized risk reduction asset. Pre-validated testing pathways for components such as 3D-printed cutting guides, spinal implants and reusable instrument trays allow development teams to slot their device into an existing validation route rather than building one from scratch. The result is a meaningful reduction in cost and timeline, with a corresponding reduction in risk at a stage when budgets are often under the most pressure.
Constant Collaboration
Ask development leaders what separates programs that cross the finish line from those that don’t, and a consistent theme emerges: the quality of the human infrastructure surrounding the technical work. The organizations that sustain program momentum through complexity are the ones that have invested in genuine relationships across every link in the development chain.
Dr. van der Wilk is direct about what she tracks to assess whether a program is on track: deliverables, budget and timeline. But she is equally direct about the less quantifiable dimension. “Good relationships and strong communication among development team members make a big difference,” she said.
That relationship orientation also applies to the way OEMs work with suppliers. In device development, supplier relationships carry a permanence that does not exist in most industries. Regulatory qualification processes create dependencies that are difficult to unwind once established. Changing suppliers mid-program is not simply a procurement decision. It often requires re-validation, re-qualification and updated regulatory documentation.
Supplier selection belongs in the risk management bucket from the earliest phases. Understanding a supplier’s true capabilities requires more than confirming ISO 13485 certification. Conducting a supplier assessment before the relationship begins avoids costly surprises later.
Stage gate reviews, when conducted rigorously by teams with genuine development experience, serve as a systematic check against the accumulation of unaddressed risk. Done well, they confirm that every deliverable required for the next phase is in place, that no assumptions have been quietly buried and that the program is building on a solid foundation at each transition.
For programs already in motion, a structured gap analysis can serve the same diagnostic function as early-phase risk mapping in new programs. Identifying gaps in the technical file, the product framework, the QMS or the organizational structure — and specifying how to close each one — gives development leaders a clear roadmap to return a program to a solid footing without halting momentum.
The relational dimension of collaboration can’t be supported entirely through digital channels, no matter how well the project management infrastructure is built. Dr. van der Wilk is emphatic on this point.
“The only way to develop trust is to meet in person. You can’t do everything via a Teams call,” she said.
For cross-border development partnerships, where time zone differences, cultural nuances and language considerations add friction to every interaction, in-person engagement is not a luxury. It is a risk management investment.
Strategic Investment
Today’s devices are more sophisticated than ever. The development processes behind them must be equally sophisticated.
Companies that will lead in the next decade of innovation are the ones building risk management into the fabric of their development culture — not as a compliance exercise, but as the discipline that makes breakthrough products possible.
